A comparative analysis between low-dose-rate brachytherapy and external beam radiation therapy for low- and intermediate-risk prostate cancer in Asian men. (3rd October 2021)

• Record Type: Journal Article
• Authors: Li, Youquan; Chan Kong Ngai, Thomas; Zhou, Siqin; Yap Haw Hwong, Jerome; Pang Pei Ping, Eric; Ong Li Kuan, Ashley; Wang Lian Chek, Michael; Chua Lee Kiang, Melvin; Looi, Wen Shen; Nei, Wen Long; Chua, Eu Tiong; On, Weber Lau Kam; Tan Wee Kiat, Terence; Yuen Shyi Peng, John; Tuan Kit Loong, Jeffrey
• Is Part Of: Acta oncologica. Volume 60:Number 10(2021)
• Page Start: 1291
• Page End: 1295
• Publication Date: 2021-10-03
• Subjects: Low-dose-rate brachytherapy -- external beam radiation therapy -- low- and intermediate-risk prostate cancer -- biochemical failure-free survival; Oncology -- Periodicals; Cancer -- Treatment -- Periodicals; 616.992
• DOI: 10.1080/0284186X.2021.1950921
• Languages: English
• ISSNs: 0284-186X

Abstract

Abstract: Objective: To report the long-term clinical outcomes of low-risk (LR) and intermediate-risk (IR) prostate cancer patients treated with low-dose-rate brachytherapy (LDR-BT) and external beam radiation therapy (EBRT). Patients and Methods: Men with biopsy-proven low- and intermediate-risk prostate cancer received EBRT and LDR-BT in an Asian academic center from 2000 to 2019 were reviewed. Kaplan–Meier survival analysis was performed to compare biochemical failure-free survival (bFFS) and overall survival (OS) between LDR and EBRT in the low- and intermediate-risk cohorts. Results: 642 patients (521 EBRT and 121 LDR-BT) with low- and intermediate-risk prostate cancer were included for analysis. In the intermediate-risk group, 5- and 10-year bFFS was 96%, 89% and 86%, 61% for LDR-BT and EBRT, respectively. LDR-BT was associated with a statistically significant improvement of bFFS in the intermediate-risk cohort (HR 2.7, p = 0.02). In the low-risk cohort, no difference of bFFS was found between LDR-BT and EBRT (HR 1.9, p = 0.08). Hormone therapy was more common in EBRT than LDR-BT for intermediate-risk group (71% versus 44%, p < 0.05). Prostate cancer-specific mortality was low in both EBRT (1%) and LDR-BT (2%) cohorts. No significant difference in OS was found between LDR-BT and EBRT in low- and intermediate-risk group (HR 2.1, p = 0.2 and HR = 1.7, p = 0.3). Conclusion: In our retrospective study, LDR-BT is associated with superior bFFS compared with EBRT in Asian men with intermediate-risk prostate cancer.